Immuneering Corporation (IMRX)
NASDAQ: IMRX · IEX Real-Time Price · USD
1.110
-0.030 (-2.63%)
At close: Jul 19, 2024, 4:00 PM
1.160
+0.050 (4.50%)
Pre-market: Jul 22, 2024, 9:00 AM EDT
Immuneering Employees
Immuneering had 68 employees as of December 31, 2023. The number of employees decreased by 5 or -6.85% compared to the previous year.
Employees
68
Change (1Y)
-5
Growth (1Y)
-6.85%
Revenue / Employee
n/a
Profits / Employee
-$796,695
Market Cap
32.92M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 68 | -5 | -6.85% |
| Dec 31, 2022 | 73 | 9 | 14.06% |
| Dec 31, 2021 | 64 | 38 | 146.15% |
| Dec 31, 2020 | 26 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Nutex Health | 800 |
| Cutera | 430 |
| Exagen | 179 |
| Retractable Technologies | 151 |
| Orgenesis | 146 |
| IRIDEX | 111 |
| ReWalk Robotics | 108 |
| ImmuCell | 79 |
IMRX News
- 7 weeks ago - Immuneering to Present at the Jefferies Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 2 months ago - Immuneering Recognizes Melanoma Awareness Month - GlobeNewsWire
- 3 months ago - IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models - GlobeNewsWire
- 3 months ago - Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 4 months ago - Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations - GlobeNewsWire
- 4 months ago - Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors - GlobeNewsWire
- 4 months ago - Immuneering Appoints Thomas J. Schall, Ph.D. - GlobeNewsWire